collection
MENU ▼
Read by QxMD icon Read
search

Neuro-progressive effects of severely treatment-resistant depression

shared collection
5 papers 0 to 25 followers
https://www.readbyqxmd.com/read/27824293/does-psychache-mediate-the-relationship-between-general-distress-and-suicide-ideation
#1
Rui C Campos, Margarida Gomes, Ronald R Holden, Margarida Piteira, Ana Rainha
This study evaluated whether psychache (i.e., mental pain) mediates the association between general distress, assessed as the frequency and the intensity of psychological symptoms in the previous week, and suicide ideation in community adults. For a sample of 202 adults, psychache fully mediated the relationship between suicide ideation and the frequency of psychological symptoms, and partially mediated the relationship between suicide ideation and the intensity of psychological symptoms. As such, mental pain fully or partially explains the process linking the frequency and the intensity of general distress to suicide ideation and, thus, mental pain is a target for potential intervention...
November 8, 2016: Death Studies
https://www.readbyqxmd.com/read/27784055/toward-an-evidence-based-operational-definition-of-treatment-resistant-depression-when-enough-is-enough
#2
Charles R Conway, Mark S George, Harold A Sackeim
No abstract text is available yet for this article.
October 26, 2016: JAMA Psychiatry
https://www.readbyqxmd.com/read/26133661/failure-of-hippocampal-deactivation-during-loss-events-in-treatment-resistant-depression
#3
Blair A Johnston, Serenella Tolomeo, Victoria Gradin, David Christmas, Keith Matthews, J Douglas Steele
Major depressive disorder is characterized by anhedonia, cognitive biases, ruminations, hopelessness and increased anxiety. Blunted responses to rewards have been reported in a number of recent neuroimaging and behavioural studies of major depressive disorder. In contrast, neural responses to aversive events remain an under-studied area. While selective serotonergic reuptake inhibitors are often effective in treating major depressive disorder, their mechanism of action remains unclear. Following a series of animal model investigations of depressive illness and serotonergic function, Deakin and Graeff predicted that brain activity in patients with major depressive disorder is associated with an overactive dorsal raphe nucleus with overactive projections to the amygdala, periaqueductal grey and striatum, and an underactive median raphe nucleus with underactive projections to the hippocampus...
September 2015: Brain: a Journal of Neurology
https://www.readbyqxmd.com/read/16841624/prediction-of-recurrence-in-recurrent-depression-and-the-influence-of-consecutive-episodes-on-vulnerability-for-depression-a-2-year-prospective-study
#4
COMPARATIVE STUDY
Claudi L H Bockting, Philip Spinhoven, Maarten W J Koeter, Luuk F Wouters, Aart H Schene
OBJECTIVE: Depression is a recurring disease. Identifying risk factors for recurrence is essential. The purpose of this study was to identify factors predictive of recurrence and to examine whether previous depressive episodes influence vulnerability for subsequent depression in a sample of remitted recurrently depressed patients. METHOD: Recurrence was examined prospectively using the Structured Clinical Interview for DSM-IV Axis I Disorders in 172 euthymic patients with recurrent depression (DSM-IV) recruited from February 2000 through September 2000...
May 2006: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/25129432/psychomotor-retardation-is-a-scar-of-past-depressive-episodes-revealed-by-simple-cognitive-tests
#5
MULTICENTER STUDY
P Gorwood, S Richard-Devantoy, F Baylé, M L Cléry-Melin, M L Cléry-Melun
The cumulative duration of depressive episodes, and their repetition, has a detrimental effect on depression recurrence rates and the chances of antidepressant response, and even increases the risk of dementia, raising the possibility that depressive episodes could be neurotoxic. Psychomotor retardation could constitute a marker of this negative burden of past depressive episodes, with conflicting findings according to the use of clinical versus cognitive assessments. We assessed the role of the Retardation Depressive Scale (filled in by the clinician) and the time required to perform the neurocognitive d2 attention test and the Trail Making Test (performed by patients) in a sample of 2048 depressed outpatients, before and after 6 to 8 weeks of treatment with agomelatine...
October 2014: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"